CCR5 and neuropathy: CCR5 is strongly upregulated in the ipsilateral dorsal spinal cord and DRGs after CCI, and the intrathecal administration of maraviroc (CCR5 antagonist) prevents these changes and, in parallel, the activation of microglia/macrophages and astroglial cells, which are known to be responsible for hypersensitivity development in neuropathy.